NetworkNewsBreaks – Cerus Corp. (NASDAQ: CERS) Says FDA Decision Could Minimize Potential PAS Supply Disruption; Shares Higher
Shares of Cerus Corp. (NASDAQ: CERS) are up 11.2% after the biomedical products company said an expected shortage of Fresenius Kabi platelet additive solution (PAS) could be less disruptive to blood center production of INTERCEPT platelets thanks to a key decision by the FDA. The agency is reviewing a recent submission by Fresenius Kabi as a Changes Being Effected in 30 Days (CBE-30) supplement to address some changes in raw materials used by the manufacturer of the PAS container. CBE-30 allows ongoing distribution of the product during the review period, which could minimize impact. “We are cautiously optimistic that a…